1219. Increasing methicillin resistance of Staphylococcus lugdunensis in a tertiary care community hospital in Japan
Session: Poster Abstract Session: Healthcare Epidemiology: MSSA, MRSA and Other Gram Positive Infections
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • idweeklugdunensis.pdf (749.9 kB)
  • Background: Staphylococcus lugdunensis, a coagulase-negative staphylococcus, has virulence and pathogenicity similar to that of Staphylococcus aureus. Methicillin resistance and presence of mecA gene are not common in S. lugdunensis in many parts of the world. Recently, higher prevalence of methicillin-resistant S. lugdunensis is reported from Taiwan and Japan. We describe the change in methicillin resistance of S. lugdunensis in a tertiary care community hospital in Sapporo, Japan.

    Methods: We performed a retrospective study of S. lugdunensis, isolated from inpatients and outpatients at our hospital from 2008 to 2017. Rate of methicillin resistance of the first 5 years from 2008 to 2012, and that of the second 5 years from 2013 to 2017 were compared. Risk factors of methicillin resistance were also evaluated. Phenotypic detection of methicillin resistance was identified using broth microdilution by VITEK 2 system (bioMérieux).

    Results: A total of 369 cases of S. lugdunensis were detected during the study period. Of all cases, 228 (61.8%) were men, and 177 (48.0%) were hospitalized. Twenty-one isolates (5.7%) were positive in blood culture, 216 (58.5%) were positive in cultures of skin and soft tissue. Methicillin-resistant strains were found in 43 (31.6%) of 136 isolates from 2008 to 2012, and in 108 (46.4%) of 233 from 2013 to 2017 (OR 1.87; 95%CI 1.20-2.91; p = 0.006). Of patients with methicillin-resistant S. lugdunensis, 105 cases (69.5%) were hospitalized (p <0.001).

    Conclusion: In our hospital, methicillin-resistant S. lugdunensis is increasing over the 10 years. Further research is needed to assess trend of methicillin resistance of S. lugdunensis in other healthcare facilities and countries.

    Takahiro Ichikawa, MD, Kenwakai Otemachi Hospital, Fukuoka, Japan and Fumihiro Kodama, MD, Sapporo City General Hospital, Sapporo, Japan

    Disclosures:

    T. Ichikawa, None

    F. Kodama, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.